StockDriftsStockDriftsTop 22 Nextbio Capital Management LP Holdings
| Stock | Company | % Port. | Shares | Value | Activity | Ownership | Avg. Cost | Date |
|---|---|---|---|---|---|---|---|---|
| PTGX | PROTAGONIST THERAPEUTICS INC | 12.37% | 219.3K | $26.9M | -4.48%(-10.29K) | $76.88(+98.20%) | 2026-06-30 | |
| STTK | SHATTUCK LABS INC | 11.9% | 3.73M | $25.9M | +18.33%(+577.44K) | $3.55(+106.12%) | 2026-06-30 | |
| CMPS | COMPASS PATHWAYS PLC | 11.56% | 1.78M | $25.1M | -12.15%(-245.65K) | $6.25(+123.60%) | 2026-06-30 | |
| GPCR | STRUCTURE THERAPEUTICS INC | 7.71% | 312.5K | $16.8M | +134.54%(+179.26K) | $50.05(+9.30%) | 2026-06-30 | |
| VOR | VOR BIOPHARMA INC | 7.53% | 889.2K | $16.4M | -11.08%(-110.80K) | $30.90(-24.63%) | 2026-06-30 | |
| RYTM | RHYTHM PHARMACEUTICALS INC | 6.73% | 131.8K | $14.6M | +4.51%(+5.68K) | $100.48(+16.03%) | 2026-06-30 | |
| PVLA | PALVELLA THERAPEUTICS INC NE | 6.32% | 89.9K | $13.7M | +8.74%(+7.22K) | $87.54(+78.36%) | 2026-06-30 | |
| XENE | XENON PHARMACEUTICALS INC | 5.09% | 183.2K | $11.1M | +0.00%(+0) | $42.49(+52.37%) | 2026-06-30 | |
| ZBIO | ZENAS BIOPHARMA INC | 4.98% | 426.7K | $10.8M | +0.00%(+0) | $28.93(-0.71%) | 2026-06-30 | |
| ORIC | ORIC PHARMACEUTICALS INC | 3.52% | 706.1K | $7.6M | +34.85%(+182.50K) | $10.46(+29.62%) | 2026-06-30 |
| Performance Metric | 3-Year Annualized | 3-Year Cumulative | 5-Year Annualized | 5-Year Cumulative | Since First Filing (2 quarters) |
|---|---|---|---|---|---|
| Top 20 Holdings Weighted | — | — | — | — | +26.20% |
| Top 20 Holdings Unweighted | — | — | — | — | +16.50% |
Nextbio Capital Management LP reports $217.40M in US-listed equity holdings across 22 positions in its most recent 13F filing. Its largest disclosed positions are PTGX (12.4%), STTK (11.9%) and CMPS (11.6%). The top 20 holdings account for 98.66% of reported assets. Its disclosed equity book has returned +26.20% cumulatively over 2 quarters. Figures reflect the Q2 2026 filing.
Portfolio changes
Every reported change this quarter, grouped by direction. The signal is in the rotation, not any single trade.
Sign up free to track Nextbio Capital Management LP, compare funds side by side, and get alerts the moment positions change.
Holdings on this page are parsed from Nextbio Capital Management LP’s Form 13F filings with the U.S. Securities and Exchange Commission (CIK 2038158). View Nextbio Capital Management LP’s 13F filings on SEC